Camlin Fine Sciences Limited
Camlin Fine Sciences is engaged in the Business of Speciality Chemicals.
What Camlin files
- Others88
- Investor Meet28
- Important23
- Updates14
- Board Meeting11
- Pledging8
Camlin Fine Sciences' board approved Q1 results. Consolidated Revenue was ₹519.88 Cr, with a net loss of ₹31.71 Cr. The company increased its stake in Vinpai S.A. to 95.41% and adopted new segment reporting.
Camlin Fine Sciences' Board approved financial results: consolidated profit of ₹86.28 Cr for Q4FY26 and ₹23.54 Cr for FY26. New CFO Pankaj Pandey was appointed, and Vinpai acquisition details were noted.
Camlin Fine Sciences has announced a board meeting today which approved the consolidated financial results for the quarter and nine months ended December 31, 2025.
Camlin Fine Sciences' board approved the financial results for the quarter and half-year, reporting a consolidated loss of ₹25.63 Cr on revenues of ₹883.38 Cr. Key decisions include re-appointing an Independent Director, subject to shareholder approval, and granting 16.23 lakh employee stock options.
Camlin Fine Sciences' Board approved issuing 41.06 lakh new equity shares at ₹247.69 each, totaling ₹101.71 Cr. This is for acquiring a 78.68% stake in French firm Vinpai via a share swap. Shareholders will vote via postal ballot.